NEOsphere Biotechnologies

NEOsphere Biotechnologies is a private, pre-revenue platform and services company focused on the high-growth field of targeted protein degradation. Its core offering integrates industrial-scale, high-throughput proteomics—specifically Deep Proteomic Screening and global ubiquitinomics—with a proprietary data analysis suite called neoVERSE to de-risk and accelerate degrader drug discovery for pharmaceutical partners. By providing unparalleled insights into degrader mechanisms, on-/off-target effects, and ubiquitin signaling, NEOsphere aims to unlock previously 'undruggable' targets and help partners build robust TPD pipelines efficiently.

Integrated proteomics platform combining Deep Proteomic Screening (high-throughput DIA-MS) and global ubiquitinomics with the neoVERSE data analysis suite to systematically identify and validate degrader targets and mechanisms for targeted protein degradation drug discovery.

NEOsphere competes in the niche of TPD-focused discovery services. Competitors include other specialized CROs offering proteomics, CRISPR screening, or structural biology services for early-stage drug discovery. Its differentiation lies in its integrated focus on proteome-wide degrader characterization and proprietary ubiquitinomics and data analysis capabilities.